Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
15
Breast cancer -- often regarded as a female illness -- can strike women and men alike, and is equally deadly for either gender. Breast cancer is the exact same condition in both sexes and affectsboth in the same way, though it is far rarer in men than women, said Dr. Joseph Pearson, a McLeod Regional Medical Center surgeon who treats breast cancer in men and women. He also serves as the cancer liaison physician for McLeod to the American College of Surgeons' Commission on Cancer.
Cryo-Cell International, a global leader in stem cell innovation, is proud to be making progress in the fight against breast cancer through research and development using stem cells from menstrual blood. In honor of National Breast Cancer Awareness Month, Cryo-Cell is supporting Susan G. Komen for the Cure through C'elle, the company's service which enables women to collect and cryopreserve stem cells from their menstrual blood.
Genomic Health, Inc. announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.
The statistics from a recent study is startling: Women diagnosed with breast cancer by a routine mammogram have a 95 percent chance of surviving. For women diagnosed later, who haven't received routine mammograms, the chance of dying is 56 percent.
A new study, 'Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial,' is now available. In advanced ovarian cancer, maximal efforts have to be attemptedto achieve optimal cytoreduction, as this represents the keystone in the therapeutic management.
NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA- approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009.
A new study is raising some concerns about robotic prostate cancer surgery, a procedure widely used by local hospitals and promoted as having fewer complications than traditional prostate surgery.
Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.
Researchers at Henry Ford Hospital have identified tumor-suppressing genes that may provide a more accurate diagnosis of disease stage and survival for laryngeal cancer patients than current standards. The study finds genetic abnormalities of the ESR1(estrogen specific receptor 1) gene and the HIC1 (hypermethylated in cancer 1) gene are predictors of late-stage laryngeal cancer and shorter survival, respectively, for patients with the disease.
14
In honor of National Breast Cancer Awareness Month, a group of women known as the BRAC (Be Ready Against Cancer) Pack has stepped up its efforts to encourage genetic testing for breast and ovarian cancer. The women are advocates for BRACAnalysis, a lab test that looks for mutations on the BRCA1 and BRCA2 genes, which are associated with an increased risk of breast and ovarian cancer.
We care about your feedback. Let us know how we can improve your CancerCompass experience.